Skip to main content

What type of lung cancer is Vizimpro used to treat?

Medically reviewed by Last updated on Oct 18, 2022.

Official answer


Vizimpro is taken for first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC).

Vizimpro (dacomitinib) from Pfizer is an oral, once-daily kinase inhibitor that targets two lung cancer biomarkers, both detected by an FDA-approved test. These two targets are:
  • Epidermal growth factor receptor (EGFR) exon 19 deletion mutations
  • EGFR exon 21 L858R substitution mutations.

Other EGFR inhibitors that may be used in the treatment of NSCLC include:

Related medical questions

Drug information

Related support groups